Global biopharmaceutical giant GSK has solidified its commitment to long-term climate neutrality through a significant eight-year agreement with the Indian nature-based solutions developer Varaha. The partnership, facilitated by the nature-focused investment platform Earthly, centers on the purchase of over 500,000 carbon removal credits derived from a large-scale regenerative agriculture initiative spanning the northern Indian states of Punjab and Haryana. This strategic move aligns with GSK’s aggressive Science Based Targets initiative (SBTi)-validated goal of reaching net zero greenhouse gas emissions across its entire value chain by 2045.
Strategic Scope and Project Mechanics
The collaboration targets the transformation of 50,000 hectares of farmland, moving traditional agricultural practices toward more sustainable, carbon-sequestering methods. Varaha, an enterprise established in 2022, has built a specialized business model focused on empowering smallholder farmers to act as stewards of carbon sequestration. By incentivizing the transition from conventional, high-emission techniques—such as intensive tillage, flood-irrigated rice cultivation, and the widespread practice of burning crop residue—to regenerative alternatives, the project addresses both climate change and regional environmental health.
The core regenerative techniques being implemented include Direct Seeded Rice (DSR), a method that significantly reduces methane emissions by avoiding the traditional flooding of fields, and the incorporation of crop residues into the soil rather than burning them. These methods not only enhance soil organic carbon (SOC) but also improve soil fertility, structural integrity, and moisture retention.
A Chronology of Climate Action
The agreement marks a milestone in GSK’s sustainability roadmap, which was formalized with a 2020 baseline for its net zero strategy.
- 2020: GSK establishes its baseline for a 90% absolute reduction in scope 1, 2, and 3 emissions.
- 2022: Varaha is founded in India with the explicit mission to sequester one billion tonnes of CO2e through smallholder-led regenerative agriculture.
- 2023–2024: GSK and Earthly evaluate various nature-based solutions to address the unavoidable residual emissions that will remain after its deep decarbonization efforts.
- 2026: Formal signing of the eight-year agreement between GSK and Varaha.
- 2028–2033: The operational delivery phase, during which approximately 100,000 tonnes of carbon removal credits are expected to be generated annually.
Quantifying the Impact: Environmental and Economic Metrics
The project is designed to deliver a dual dividend: verifiable climate benefits and tangible socioeconomic gains for local farming communities. During the project’s initial monitoring period, covering 42,000 hectares, the impact was profound. The reduction in crop residue burning led to the avoidance of 4,574 tonnes of PM2.5 (fine particulate matter) emissions, directly contributing to improved air quality in a region notorious for severe seasonal smog. Furthermore, the transition to more efficient irrigation practices saved an estimated 59.5 billion liters of water.
From an economic perspective, the project serves as a model for "inclusive climate action." By providing participating farmers with subsidized access to modern, low-impact machinery and a share of the revenue generated from carbon credits, the project has successfully created a new income stream. During the first monitoring phase, households involved in the program reported a 12% to 16% increase in average income. This rise in prosperity is attributed to a combination of improved crop yields, reduced expenditure on fertilizers, and the direct financial dividends from the carbon credit market.
Official Perspectives on the Partnership
Adele Cheli, Vice President of Environmental Sustainability at GSK, emphasized the strategic importance of the deal, noting that the company views environmental health as intrinsically linked to human health. "For GSK, environmental sustainability is core to business resilience and human health," Cheli stated. "This investment demonstrates how we are progressing in our net-zero journey, whilst also delivering co-benefits for human health, nature, and local communities."
Madhur Jain, Co-founder and CEO of Varaha, provided context regarding the scale of the challenge in India, where an estimated 100 million tonnes of crop residue are burned annually. "For a smallholder with a few days between harvest and sowing, fire is free and every alternative costs money," Jain explained. "We work with more than 200,000 farming families, and the lesson is consistent: burning stops when the alternative pays. Credit revenue pays for the equipment and the extra labour." Jain underscored that while this agreement covers 50,000 hectares, the systemic change required to address the issue across millions of hectares depends on long-term, cross-sectoral commitments.
Implications for the Pharmaceutical Industry
GSK’s procurement of 100,000 tonnes of annual carbon removal credits represents approximately 7% of the company’s projected residual emissions. This is a critical component of its "net-zero by 2045" strategy. For a multinational pharmaceutical firm, the challenges of decarbonizing a complex global supply chain are immense, involving everything from chemical manufacturing processes to cold-chain logistics.
The decision to lean into high-quality, nature-based carbon removals—rather than relying solely on avoidance-based offsets—marks a significant shift in corporate climate strategy. By supporting regenerative agriculture, GSK is effectively investing in "insetting" or high-integrity removals that offer clear, verifiable environmental co-benefits. This approach aligns with the growing scrutiny from regulators and ESG investors who demand that companies move beyond simple emission offsets to address the broader ecological impacts of their operations.
Analysis of the Carbon Market Integration
The role of Earthly, the nature-focused investment platform that structured the deal, highlights the maturation of the voluntary carbon market (VCM). As companies face increased pressure to substantiate their net-zero claims, the demand for "high-quality" credits—those that are measurable, permanent, and socially beneficial—has surged.
The Varaha project serves as a test case for how technology and finance can bridge the gap between smallholder farmers and global corporate climate goals. By using digital monitoring, reporting, and verification (MRV) systems, Varaha ensures that the carbon sequestration is accurately measured. This level of transparency is essential for multinational corporations like GSK, which must satisfy strict internal and external audits regarding their sustainability disclosures.
Future Outlook and Scalability
While the 50,000-hectare agreement is a significant step forward, the broader implication is the potential for replication. If the model of using carbon finance to subsidize the transition to DSR and reduced tillage proves sustainable over the eight-year duration of the contract, it could provide a blueprint for other agricultural regions facing similar environmental pressures.
The success of this program will likely be measured not just in tonnes of CO2 sequestered, but in the retention of farmers within the regenerative system once the initial subsidies are phased out or as the agricultural market adjusts to new practices. As GSK continues to work toward its 2045 deadline, the partnership with Varaha stands as a prime example of how the pharmaceutical sector can leverage its capital to influence sustainable development in emerging markets, effectively turning climate risk management into a force for social and environmental progress.
The collaboration remains a pivotal development in the intersection of health, agriculture, and corporate climate responsibility, demonstrating that the path to net zero is increasingly paved with projects that provide measurable, local, and human-centric benefits.
